Immuno Technologies

Executive Summary

Immuno Technologies (ITi) is a preclinical-stage biotechnology company based in San Diego, CA, with operations in Memphis, TN. The company specializes in developing preventatives, including vaccines and monoclonal antibody therapies, as well as diagnostic assays for Lyme disease and leptospirosis. These infectious diseases represent significant unmet medical needs, particularly in endemic regions where current prevention and diagnostic options are limited. ITi's approach leverages proprietary technologies to create targeted biologics and rapid diagnostics, aiming to improve patient outcomes and public health surveillance. Founded in 2014, the company operates as a private entity and has not yet disclosed funding rounds or valuation, reflecting its early stage of development. Given its preclinical status, Immuno Technologies has not yet advanced any candidates to clinical trials or generated revenue. The company's near-term value drivers depend on successful completion of preclinical studies, securing partnerships, and obtaining grant funding to support IND-enabling activities. While the potential market for Lyme and leptospirosis interventions is substantial, the path to commercialization involves significant technical and regulatory risks. Investors should monitor progress on animal model efficacy data and collaborative agreements as key milestones. The company's ultimate success hinges on demonstrating a clear differentiation in efficacy and manufacturability compared to existing and pipeline competitors.

Upcoming Catalysts (preview)

• TBDPreclinical efficacy data for Lyme disease vaccine candidate30% success
• TBDPartnership or licensing deal for leptospirosis diagnostic assay25% success
• TBDGrant award from NIH for leptospirosis monoclonal antibody therapy40% success